Deborah Autor Sells 34,819 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Deborah Autor sold 34,819 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director owned 93,660 shares in the company, valued at approximately $1,211,960.40. This trade represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Amneal Pharmaceuticals Stock Down 1.7%

Shares of NASDAQ:AMRX opened at $12.39 on Thursday. Amneal Pharmaceuticals, Inc. has a 12 month low of $7.02 and a 12 month high of $15.42. The company’s fifty day simple moving average is $12.70 and its 200 day simple moving average is $12.80. The firm has a market cap of $3.90 billion, a price-to-earnings ratio of 32.61 and a beta of 1.32.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.27 EPS for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. The business had revenue of $722.52 million for the quarter. Research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. UBS Group started coverage on shares of Amneal Pharmaceuticals in a research note on Friday, April 17th. They issued a “buy” rating and a $19.00 price target on the stock. Weiss Ratings raised shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday. Truist Financial lifted their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in AMRX. Assenagon Asset Management S.A. increased its position in Amneal Pharmaceuticals by 75.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock worth $47,398,000 after purchasing an additional 1,611,698 shares in the last quarter. Westshore Wealth LLC bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at $13,833,000. Morgan Stanley boosted its stake in shares of Amneal Pharmaceuticals by 37.5% in the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after purchasing an additional 1,315,018 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Amneal Pharmaceuticals by 72.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock valued at $32,405,000 after purchasing an additional 1,069,400 shares during the last quarter. Finally, Penn Capital Management Company LLC bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at $12,655,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.